Careers
Press Releases
Newsroom
Investor Relations
Privacy Policy
Site Directory
Terms & Conditions
| The world’s leader in diagnostic |
|
|
|
|
|
|
Physicians: ePrescribing can help you qualify for the CMS 2% incentive payment. Now with our limited time offer, you can try ePrescribing for 6 months — and if it doesn't meet your needs, cancel and pay no monthly fees.
Use our Drug Testing Return on Investment Calculator to learn how much money your company can save with a drug testing program through Quest Diagnostics.
Physicians and patients: Learn about testing options for the 2009 H1N1 Influenza Virus.
Read the latest Quest Diagnostics Health Trends™ Report about the behavior of the 2009 H1N1 flu virus, based on our testing data.
Watch the video "Beat the Disease to the Market" to learn Quest Diagnostics' approach to developing diagnostics for infectious diseases.
Physicians: Empower your patients to get their results online and take a more active role in their health.
Patients: Get your lab results online with: Google Health™, Keas™, MicroSoft®, HealthVault™ or Quest Diagnostics’ MyCare360.
We offer several programs to assist patients facing financial difficulty, including our Financial Assistance Program, free or reduced fee laboratory services, and our participation in the Take Care Recovery Plan.
H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics
| - | Quest Diagnostics Health Trends™ Report based on results of more than 142,000 patient specimens tested for 2009 H1N1 influenza virus since May 2009 |
| - | Hair data reveal higher use for certain drugs than urine data alone reflect |
| - | First large-scale analysis of same-donor hair and urine specimens draws useful distinctions between test methods |
| - | Simplexa™ molecular RT-PCR test runs on the 3M Integrated Cycler; employs RT-PCR technologies comparable to 2009 H1N1 flu test used by World Health Organization |
Quest Diagnostics Reports Strong Performance in Third Quarter 2009
| - | Total revenues of $1.9 billion, up 3.9%; |
| - | Diluted earnings of $1.02 per share, up 26% |
| - | Cash flow from operations of $374 million, up 14% |
| - | 2009 EPS outlook increased to a range of $3.80 to $3.85 |
| - | Listen to a replay of Quest Diagnostics' Third Quarter Conference Call. |
| - | Read a Transcript of Company Prepared Comments |
| - | Test runs on the 3M Integrated Cycler; Reflects first Simplexa™ branded molecular test kit from Focus Diagnostics |
| - | First saliva-based cardiovascular disease test from Quest Diagnostics identifies gene variants implicated in potentially lethal reaction to popular anti-clotting drug |
Quest Diagnostics Empowers the Nation's Physicians to Immediately Embrace ePrescribing
| - | Company to Enable All Care360™ Labs & Meds Users to Use ePrescribing Feature; Invites All U.S. Physicians to Use Care360 ePrescribing Risk Free for Six Months |
| - | First lab test that can indicate ovarian cancer prior to biopsy or exploratory surgery |